The DOI matches its Crossref record; 135 of the 135 references it cites were found in a registry or an index.
Targeted and armed oncolytic poxviruses: a novel multi-mechanistic therapeutic class for cancer
Abstract
Viruses have been engineered for cancer therapy in a variety of ways. Approaches include non-replicating gene therapy vectors, cancer vaccines and oncolytic viruses, but the clinical efficacy of these approaches has been limited by multiple factors. However, a new therapeutic class of oncolytic poxviruses has recently been developed that combines targeted and armed approaches for treating cancer. Initial preclinical and clinical results show that products from this therapeutic class can systemically target cancers in a highly selective and potent fashion using a multi-pronged mechanism of action.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Moreover, oncolytic viruses can be armed with vectors that encode for pro-inflammatory or anti-immunosuppressive transgenes, thereby in theory promoting both the immunogenicity of the tumour cells and intratumoral inflammation.128”
From Current and emerging concepts for systemic treatment of metastatic colorectal cancer (2025) · cites this paper as [128]
Citations
Cites
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Cancer immunotherapy: moving beyond current vaccines
Rosenberg, S. A., Yang, J. C.-H., & Restifo, N. P. (2004) · Nature Medicine · doi:10.1038/nm1100 · Cited by 2,980
Demetri, G. D., van Oosterom, A. T., Garrett, C. R., Blackstein, M. E., Shah, M. H., Verweij, J., McArthur, G. A., Judson, I. R., Heinrich, M. C., Morgan, J. A., et al. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69446-4 · Cited by 2,639
Cancer regression in patients after transfer of genetically engineered lymphocytes
Morgan, R. A., Dudley, M. E., Wunderlich, J. R., Hughes, M. S., Yang, J. C., Sherry, R. M., Royal, R. E., Topalian, S. L., Kammula, U. S., Restifo, N. P., et al. (2006) · Science · doi:10.1126/science.1129003 · Cited by 2,603
High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal
Lotze, M. T., & Tracey, K. J. (2005) · Nature reviews. Immunology · doi:10.1038/nri1594 · Cited by 2,490
An Adenovirus Mutant That Replicates Selectively in p53- Deficient Human Tumor Cells
Bischoff, J. R., Kirn, D. H., Williams, A., Heise, C. C., Horn, S. T., Muna, M., Ng, L., Nye, J. A., Sampson-Johannes, A., Fattaey, A., et al. (1996) · Science · doi:10.1126/science.274.5286.373 · Cited by 1,769
Self-citation(1988) · World Health Organization eBooks · Cited by 1,574
Choi, H., Charnsangavej, C., Faria, S., Macapinlac, H., Burgess, M., Patel, S. R., Chen, L. L., Podoloff, D., & Benjamin, R. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.3049 · Cited by 1,508
Elwood, J. M. (1989) · Journal of Epidemiology & Community Health · doi:10.1136/jech.43.1.92 · Cited by 1,412
Khuri, F. R., Nemunaitis, J. J., Ganly, I., Arseneau, J. C., Tannock, I. F., Romel, L., Gore, M. E., Ironside, J. A. D., MacDougall, R. H., Heise, C. C., et al. (2000) · Nature Medicine · doi:10.1038/78638 · Cited by 1,099
Self-citation
Flagged first, then by citations
Research works printed but not linked: 2
- Moss, B. in Field's Virology Ch. 84 (eds Fields, B. N., Knipe, D.M. & Howley, P. M.) (Lippincott-Raven, Philadelphia, 2001).
- Burdick, K. H. Malignant melanoma treated with vaccinia injections. Arch. Dermatol. 82, 438–439 (1960).
Cited by
Sorted by citations
Items 401–401 of 401
Logical Circuits for Vaccinia Virus Vectors
Larson, & Peter, J. (2015)
Metadata
- Authors
- Kirn, D. H., & Thorne, S. H.
- ORCID
- Kirn, David H.
- Venue
- Nature Reviews Cancer
- Published
- 2009-01
- Volume
- 9
- Issue
- 1
- Pages
- 64-71
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W2079647238
- Cited by
- 402
- References
- 134
- Citations by year
- 2026: 7 · 2025: 7 · 2024: 19 · 2023: 14 · 2022: 16 · 2021: 16 · 2020: 20 · 2019: 14 · 2018: 16 · 2017: 24 · 2016: 25 · 2015: 29 · 2014: 29 · 2013: 49 · 2012: 36
- FWCI
- 2.47
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- Locations
- Nature reviews. Cancer (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Immunology and Microbiology › Virology › Poxvirus research and outbreaks
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biotechnology › Bacterial Cancer Therapy
- Keywords
- vaccinia virus, cancer gene therapy, cancer vaccines, viral vectors
- MeSH terms
- Animals, Forecasting, Humans, Immunity, Cellular, Inflammation, Neoplasm Metastasis, Neoplasms, Poxviridae, Vaccinia virus, Virus Replication, Gene Expression Regulation, Viral, Cancer Vaccines, Oncolytic Virotherapy, Oncolytic Viruses, Mice, Host-Pathogen Interactions
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
